Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one
2. 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one
3. Methyl-naltrexone Hydrobromide
4. Methylnaltrexone
5. Morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-
6. Morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, Bromide, (5alpha,17r)-
7. Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-
8. Mrz 2663br
9. Mrz-2663
10. N-methylnaltrexone Bromide
11. Naltrexone Mb
12. Naltrexone Methobromide
13. Naltrexone Methylbromide
14. Naltrexonium Methiodide
15. Quaternary Ammonium Naltrexone
16. Relistor
1. Naltrexone Methobromide
2. 73232-52-7
3. Relistor
4. Methylnaltrexone (bromide)
5. Methylnaltrexone
6. Moa-728
7. N-methylnaltrexone Bromide
8. Mrz-2663br
9. Mntx
10. Moa 728
11. Relistor (tn)
12. N-cyclopropylmethyl-noroxymorphone Methobromide
13. Relistormoa-728
14. Mntx-302
15. Moa728
16. Schembl2798188
17. Chembl1201770
18. Dtxsid30868236
19. Ono-3849
20. Methylnaltrexone Bromide (jan/usan)
21. Akos015896214
22. Cs-0762
23. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one,bromide
24. Ac-32482
25. Hy-75766
26. Methylnaltrexone Bromide, >=97% (hplc)
27. D06618
28. Methylnaltrexone Bromide, United States Pharmacopeia (usp) Reference Standard
29. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one;bromide
Molecular Weight | 436.3 g/mol |
---|---|
Molecular Formula | C21H26BrNO4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 435.10452 g/mol |
Monoisotopic Mass | 435.10452 g/mol |
Topological Polar Surface Area | 66.8 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 664 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Relistor |
PubMed Health | Methylnaltrexone (Injection) |
Drug Classes | Gastrointestinal Agent |
Drug Label | RELISTOR (methylnaltrexone bromide) injection, a peripherally-acting mu-opioid receptor antagonist, is a sterile, clear and colorless to pale yellow aqueous solution. The chemical name for methylnaltrexone bromide is (R)-N-(cyclopropylmethyl) noroxym... |
Active Ingredient | Methylnaltrexone bromide |
Dosage Form | Injectable; Solution |
Route | Subcutaneous |
Strength | 8mg/0.4ml; 12mg/0.6ml (12mg/0.6ml) |
Market Status | Prescription |
Company | Salix Pharms |
2 of 2 | |
---|---|
Drug Name | Relistor |
PubMed Health | Methylnaltrexone (Injection) |
Drug Classes | Gastrointestinal Agent |
Drug Label | RELISTOR (methylnaltrexone bromide) injection, a peripherally-acting mu-opioid receptor antagonist, is a sterile, clear and colorless to pale yellow aqueous solution. The chemical name for methylnaltrexone bromide is (R)-N-(cyclopropylmethyl) noroxym... |
Active Ingredient | Methylnaltrexone bromide |
Dosage Form | Injectable; Solution |
Route | Subcutaneous |
Strength | 8mg/0.4ml; 12mg/0.6ml (12mg/0.6ml) |
Market Status | Prescription |
Company | Salix Pharms |
Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
A06AH01
A06AH01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A06 - Drugs for constipation
A06A - Drugs for constipation
A06AH - Peripheral opioid receptor antagonists
A06AH01 - Methylnaltrexone bromide
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26528
Submission : 2012-09-14
Status : Active
Type : II
NDC Package Code : 51634-3248
Start Marketing Date : 2024-07-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30173
Submission : 2016-12-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-12-08
Pay. Date : 2014-07-28
DMF Number : 22553
Submission : 2009-02-16
Status : Active
Type : II
NDC Package Code : 0406-0151
Start Marketing Date : 2013-12-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-06-05
Pay. Date : 2020-03-05
DMF Number : 31803
Submission : 2020-03-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8948
Submission : 1991-01-24
Status : Inactive
Type : II
NDC Package Code : 0406-0151
Start Marketing Date : 2013-12-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15837
Submission : 2002-01-31
Status : Inactive
Type : II
NDC Package Code : 0406-0151
Start Marketing Date : 2013-12-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
About the Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class quality in the Midd...
About the Company : Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction & pain management. We manufacture & market a wide range of APIs & formul...
About the Company : Mallinckrodt Pharmaceuticals is a multibillion dollar specialty biopharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to addr...
About the Company : OmnisMed Pharmaceuticals believes that good healthcare must be accessible to everyone; That is the core of our philosophy. We are experts in providing a wide range of high-quality ...
About the Company : As an internationally renowned outsourcing partner, we offer products and tailor-made service packages that are seamlessly embedded in the value chain of our customers. Our pharmac...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Methylnaltrexone Bromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methylnaltrexone Bromide, including repackagers and relabelers. The FDA regulates Methylnaltrexone Bromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methylnaltrexone Bromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Methylnaltrexone Bromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Methylnaltrexone Bromide supplier is an individual or a company that provides Methylnaltrexone Bromide active pharmaceutical ingredient (API) or Methylnaltrexone Bromide finished formulations upon request. The Methylnaltrexone Bromide suppliers may include Methylnaltrexone Bromide API manufacturers, exporters, distributors and traders.
click here to find a list of Methylnaltrexone Bromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Methylnaltrexone Bromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Methylnaltrexone Bromide active pharmaceutical ingredient (API) in detail. Different forms of Methylnaltrexone Bromide DMFs exist exist since differing nations have different regulations, such as Methylnaltrexone Bromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Methylnaltrexone Bromide DMF submitted to regulatory agencies in the US is known as a USDMF. Methylnaltrexone Bromide USDMF includes data on Methylnaltrexone Bromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Methylnaltrexone Bromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Methylnaltrexone Bromide suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Methylnaltrexone Bromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Methylnaltrexone Bromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Methylnaltrexone Bromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Methylnaltrexone Bromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Methylnaltrexone Bromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Methylnaltrexone Bromide suppliers with NDC on PharmaCompass.
Methylnaltrexone Bromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Methylnaltrexone Bromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methylnaltrexone Bromide GMP manufacturer or Methylnaltrexone Bromide GMP API supplier for your needs.
A Methylnaltrexone Bromide CoA (Certificate of Analysis) is a formal document that attests to Methylnaltrexone Bromide's compliance with Methylnaltrexone Bromide specifications and serves as a tool for batch-level quality control.
Methylnaltrexone Bromide CoA mostly includes findings from lab analyses of a specific batch. For each Methylnaltrexone Bromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Methylnaltrexone Bromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Methylnaltrexone Bromide EP), Methylnaltrexone Bromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methylnaltrexone Bromide USP).
LOOKING FOR A SUPPLIER?